Lv51
1080 积分 2021-12-16 加入
感谢科研通大公无私。
Brief Report: Osimertinib Plus Capmatinib for Patients with MET-Altered EGFR-Mutant NSCLC following progression on front line therapy
8天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
8天前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
13天前
已完结
Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study
13天前
已完结
The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer
15天前
已完结
Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials
15天前
已完结
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
20天前
已完结
N-of-1 Studies in an Era of Precision Medicine
22天前
已完结
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
23天前
已完结
Pan-cancer human brain metastases atlas at single-cell resolution
26天前
已完结
皖公网安备34019202002308
